Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

The oncologist - 1 Jan 2011

Nucera Carmelo, Nehs Matthew A, Nagarkatti Sushruta S, Sadow Peter M, Mekel Michal, Fischer Andrew H, Lin Paul S, Bollag Gideon E, Lawler Jack, Hodin Richard A, Parangi Sareh

Abstract excerpt

PURPOSE: B-Raf(V600E) may play a role in the progression from papillary thyroid cancer to anaplastic thyroid cancer (ATC). We tested the effects of a highly selective B-Raf(V600E) inhibitor, PLX4720, on proliferation, migration, and invasion both in human thyroid cancer cell lines (8505c(B-RafV600E) and TPC-1(RET/PTC-1 and wild-type B-Raf)) and in primary human normal thyroid (NT) follicular cells engineered with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Growth Processes
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mass Spectrometry

Share to Mice, SCID

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Sulfonamides

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 21355020
DOI: 10.1634/theoncologist.2010-0317
PMCID: PMC3073446

Genes

RET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.PMID 21355020Read ↗

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma.Semantic proximity Read ↗

Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.Semantic proximity Read ↗

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapiesSemantic proximity Read ↗

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.Semantic proximity Read ↗

Updates on the Management of Thyroid Cancer.Semantic proximity Read ↗

Clinical and Translational Challenges in Thyroid Cancer.Semantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read ↗

Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.Semantic proximity Read ↗

Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment StrategySemantic proximity Read ↗

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.